Alligator Bioscience AB (publ) Interim Report January-March 2020
STOCKHOLM, April 23, 2020 /PRNewswire/ -- Stronger focus on clinical projects
"The focusing of our operations protects the company's liquidity, but is also part of our long-term strategy with a emphasis on clinical projects and innovation," CEO Per Norlén comments.
Significant events January-March
Andreas Johannesson was appointed interim CFO.
The COVID-19 pandemic impacts the recruitment of new patients to the company's ongoing Phase clinical I studies with the ATOR-1015 and ATOR-1017 drug candidates.
Events after the end of the period
Decision on stronger focus on the clinical development portfolio aimed at securing the value of clinical drug candidates:
Innovation platform as well as capacity and competence for discovery research retained to ensure the company's long-term development.
The company gave notice of employee reductions impacting 12 positions, corresponding to slightly more than 20% of the company's workforce.
ATOR-1015: The Phase I clinical study progressed well with ten dose levels evaluated for initial safety. Currently, evaluation is in progress of doses of 600 mg, approximately 10 mg/kg, administered every two weeks.
Financial summary
January-March
Net sales, SEK 0.0 million (0.0).
Operating result, SEK -44.9 million (-46.2).
Result for the period, SEK -42.9 million (-44.4).
Earnings per share before and after dilution, SEK -0.60 (-0.62).
Cash flow for the period, SEK 5.4 million (-34.3).
Cash and cash equivalents, incl. interest-bearing securities, SEK 203.2 million (249.9).
Read the complete report in the pdf below.
This information is such as Alligator Bioscience AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 8:00 a.m. CEST on April 23, 2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: mitazalimab, ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.) and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit http://www.alligatorbioscience.com/.
Sugar Kayne Radio, an innovative internet radio station founded by Matthew Kayne, also known as DJ Sugar Kayne, is set to launch on 2nd June. Located in the heart of North West London, Sugar Kayne Radio aims to revolutionize the online music...
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:
Today, the FDA published the FDA Voices: "A Milestone in Facilitating the Development of Safe and Effective Biosimilars," by Sarah Yim,...
Curve Health, a trailblazer in innovative healthcare solutions, is proud to announce a strategic partnership with MindCare, a leading provider of behavioral health services, with a focus on enhancing care delivery within Skilled Nursing Facilities...
Yoneda Labs, the Y Combinator startup building a foundation model for chemists working in drug discovery, today announced it has raised $4 million in seed capital from Khosla Ventures, 500 Emerging Europe, 468 Capital, Fellows Fund, and Y Combinator....
People USA, funded by and in partnership with the New York State Office of Mental Health (OMH), is set to open 20 new scattered site housing units that will support individuals re-entering the community from New...
Harbor Point at Centerville, a Benchmark Mind & Memory Care community, has ranked among the best assisted living with memory care communities in Massachusetts and the entire U.S. for the third straight year. In U.S. News & World Report's third annual...